ASX:RACBiotechs
Are Race Oncology's (ASX:RAC) New Bisantrene Patents a Turning Point for Its Competitive Edge?
Earlier this week, Race Oncology announced a scientific discovery regarding the composition of the chemotherapy drug Bisantrene and has filed three patent applications based on these findings.
This move highlights the company’s continued research efforts to strengthen its intellectual property protection in the oncology treatment space.
We’ll explore how Race Oncology’s patent applications on new Bisantrene discoveries may influence its investment narrative and future opportunities.
Find...